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Neurodegenerative disorders are a major public
health problem because of the high frequency of
these diseases. Genome editing with the CRISPR/
Cas9 system is making it possible to modify the
sequence of genes linked to these disorders. We
designed the KamiCas9 self-inactivating editing sys-
tem to achieve transient expression of the Cas9 pro-
tein and high editing efficiency. In the first applica-
tion, the gene responsible for Huntington’s disease
(HD) was targeted in adult mouse neuronal and glial
cells. Mutant huntingtin (HTT) was efficiently inacti-
vated in mousemodels of HD, leading to an improve-
ment in key markers of the disease. Sequencing of
potential off-targets with the constitutive Cas9 sys-
tem in differentiated human iPSC revealed a very
low incidence with only one site above background
level. This off-target frequency was significantly
reduced with the KamiCas9 system. These results
demonstrate the potential of the self-inactivating
CRISPR/Cas9 editing for applications in the context
of neurodegenerative diseases.
INTRODUCTION
Neurodegenerative diseases are a major public health issue and
they pose a difficult challenge in medicine. They are the leading
cause of age-related chronic diseases, and their prevalence is
rapidly increasing with changes in the population, including
greater life expectancy (Wu et al., 2016). These diseases result2980 Cell Reports 20, 2980–2991, September 19, 2017 ª 2017 The A
This is an open access article under the CC BY license (http://creativefrom monogenic mutations or from a combination of multiple
genetic and aged-related risk factors in given environmental
conditions, and their underlying pathophysiological mechanisms
are complex. Symptoms generally begin in adulthood and the
manipulation of genes linked to these disorders in post-mitotic
adult cells. It is challenging to improve our understanding of
these conditions or to target the causal genes for treatment
(Izpisua Belmonte et al., 2015; Yang et al., 2016).
Huntington’s disease (HD) is a well-characterized pathology,
which could be used as a representative neurodegenerative dis-
order to improve current therapeutic approaches. HD is caused
by a single genetic mutation on exon 1 of the huntingtin (HTT)
gene, conferring a selective vulnerability of striatal spiny projec-
ting neurons (Bates et al., 2015). Currently, there is no treatment
for HD. Considering that the mutation is a toxic gain-of-function,
a promising approach would be to decrease the expression level
of the mutant HTT (Ross and Tabrizi, 2011). This has been
already achieved with the use of RNA silencing tools, which
demonstrated that a partial mutant HTT knockdown is sufficient
to induce long-term decreases in mutant HTT-positive aggre-
gates, behavioral improvements, and reduction of neuronal
dysfunction and death (Boudreau et al., 2009; Cambon et al.,
2017; Drouet et al., 2009; Southwell et al., 2012). This approach
is currently under evaluation in a phase I/II clinical trial with
antisense oligonucleotides (Smith et al., 2016). However, RNA
silencing only provides a partial and transient HTT suppression,
and an approach ensuring a complete and permanent HTT
disruption would be preferable. This can be achieved with
genome-editing technologies, in particular the recently charac-
terized CRISPR/Cas9 system.
The CRISPR/Cas9 system is a powerful new technology in
which the Cas9 nuclease is directed to a specific genomic region
with a single-guide RNA (sgRNA) (Mali et al., 2013; Shalem et al.,uthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Evaluation of In Vivo Genome Editing in Striatal Neuronal and Glial Cells and in Human Neurons Derived from iPSCs
(A) Confocal acquisitions (left) and mean eGFP fluorescence intensity quantifications (right), 4 weeks post-infection, revealed significantly lower levels of eGFP
fluorescence in mouse striatal neurons (up, CRISPR-GFP: n = 4; sgGFP1-only, n = 4) and astrocytes (down, CRISPR-GFP: n = 10; sgGFP1-only, n = 8) infected
with CRISPR-GFP than in controls (sgGFP1-only).
(B) Genomic DNA from the injected area was extracted, and the eGFP cassette was amplified by PCR to check for indels. Surveyor analysis showed that eGFP
was efficiently edited in both cell types (neurons, CRISPR-GFP: n = 10, sgGFP1-only, n = 8; astrocytes, CRISPR-GFP: n = 4, sgGFP1-only, n = 4).
(C) eGFP PCR products from one CRISPR-GFP sample were inserted into a plasmid for Sanger sequencing. Nine of the eGFP sequences analyzed contained
indels.
(legend continued on next page)
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2015) to cleave the DNA target sequence. This system has been
successfully used to correct mutations in genetic diseases of pe-
ripheral organs and to target genes in the brain (Kolli et al., 2017;
Long et al., 2016; Monteys et al., 2017; Nelson et al., 2016; Shin
et al., 2016, 2017; Swiech et al., 2015; Tabebordbar et al., 2016).
One major challenge for CNS applications is the development of
a system allowing transient expression of the Cas9 nuclease in
order to improve the biosafety and limit off-target events. Here,
we developed the KamiCas9 self-inactivating system ensuring
transient expression of the Cas9 protein with on-target perfor-
mance similar to CRISPR/Cas9. We used the non-homologous
end-joining (NHEJ) pathway, active in post-mitotic cells, to inac-
tivate the gene implicated in HD and demonstrate high HTT edit-
ing in neurons derived from HD-induced pluripotent stem cells
(iPSCs) and in the striatum of mice. HTT inactivation was associ-
ated with a drastic reduction of HTT aggregate formation and
reduced neuronal dysfunctions, confirming the potential of the
approach. Finally, sequencing demonstrates low off-target inci-
dence, which is further decreased when KamiCas9 is used to
target HTT.
RESULTS
We took advantage of the large cloning capacity of lentiviral
vectors (LV) and their high transduction efficiencies, safety,
and long-term expression in the CNS to optimize the CRISPR/
Cas9 system delivery (Cartier et al., 2009; Jarraya et al., 2009;
Naldini et al., 1996). We first assessed the system in human
embryonic kidney 293T (HEK293T) cells carrying various copies
of an artificial mCherry-eGFP target sequence (Figure S1). The
sequence of the mCherry reporter gene is followed by a target
sequence (sgTARGET) containing a stop codon and finally a
GFP reporter gene (Figure S1A). In the control condition, only
themCherry reporter genewas expressed, whereas gene editing
by the sgTARGET destroyed the stop codon and rescue GFP
expression (Figures S1A and S1F). To characterize the kinetic
and potential limiting factors, we generated TARGET-IP
HEK293T cell populations with 12, 32, 52, and 91 integrated se-
quences in their genomes (Figures S1B and S1C) and examined
the kinetics of the reaction and importance of Cas9:sgRNA ratio
on indels efficiency (Figures S1D and S1E). These experiments
revealed that a 1:1 ratio between Cas9:sgRNA is optimal and
that the number of target sequences is affecting the kinetics of
genome editing, but not the final efficiency, which reached a
plateau in all conditions after 10–14 days, as expected from
the biology of CRISPR/Cas9 (Figures S1D–S1F).
Based on these initial evaluations, we next assessed the edit-
ing efficiency of the enhanced green fluorescent protein (eGFP)
gene in mouse primary cultures (Figure S2). Cortical neurons or
astrocytes were infected with LV expressing eGFP, Cas9, and
tdTomato-sgGFP1, or as negative control with LV-eGFP and
LV-tdTomato-sgGFP1 (Figure S2). In the control group, a large(D) Evaluation of eGFP editing in human neurons derived from induced pluripoten
the CRISPR-GFP group (n = 3, N = 2) than in controls (n = 3, N = 2) in MAP2-pos
(E) Surveyor analysis on the eGFP sequence confirmed the presence of indels in
results are presented as mean ± SD. ***p < 0.001. Scale bar, 50 mm.
See also Figures S3–S5.
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porter genes (Figures S2E, S2G, and S2I). In contrast, the mean
eGFPfluorescence intensitywas reduced inCRISPR-edited cells
with a large proportion of tdTomato-positive and GFP-negative
cells (Figures S2D, S2F, and S2H). To exclude biases in the
experimental conditions, we measured eGFP protein by western
blot and showed equivalent expression levels in both groups
(data not shown). Quantification of indels in cortical neuron (Fig-
ure S2B) and astrocyte cultures (Figure S2C) with the Surveyor
assay (Cong et al., 2013) corroborated these results and demon-
strated the high efficiency and reproducibility of GFP editing.
High in vivo editing is a crucial parameter for the development
of CNS editing and to reach therapeutic benefits. We therefore
performed a proof-of-principle GFP editing study in striatal
cell-types affected in HD (Ross and Tabrizi, 2011). LV-Cas9
and LV-sgRNAwere premixed in equal amounts and striatal neu-
rons and astrocytes were transduced with vectors specifically
targeting these cells. The neuronal tropism was obtained with
VSV-G-pseudotyped LV and a phosphoglycerate kinase pro-
moter driving the expression of the transgene (De´glon et al,
2000). Microscopy observations showed a large number of neu-
rons expressing the mCherry fluorescent protein present in the
vector expressing the guide RNA (Figures S3A and S3B). This
result confirms the high transduction efficiency of LV in the
CNS (100,000–150,000 infected cells in the striatumwith a single
injection of LV (Colin et al., 2009; de Almeida et al., 2002). For the
glial targeting, the GfaABC1D(B)3 promoter derived from the
GFAP promoter and a miR124T detargeting sequence were
used (Figure S4) (Colin et al., 2009; de Leeuw et al., 2006; Meri-
enne et al., 2013). Mosaic acquisitions and eGFP fluorescence
intensity quantifications revealed a strong loss of fluorescence
in the neurons (97%) or astrocytes (67%) of the CRISPR-GFP
groups (Figure 1A). No alteration of the striatal markers NeuN
and DARPP-32 (Bibb et al., 2000; Luthi-Carter et al., 2000; Oui-
met et al., 1998; van Dellen et al., 2000) or reporter gene expres-
sion was detected, confirming the absence of impact of LVs and
Cas9 expression in the brain (Figure S3A). Surveyor analysis on
whole striatal tissues from these animals indicated that about
50% of the neurons and 15% of the astrocytes had undergone
editing (Figure 1B). The difference between neurons and astro-
cytes reflects a bias due to the relative number of neuronal and
glial cells (>70% neurons; unpublished data) in the striatum (Fig-
ure S3D) and additional caveats. In particular, the presence of
transduced and non-transduced cells in the striatal punches
(Figure S3D) and the fact that if editing frequency is sufficiently
high, mutated sequences in homoduplexes are not detected
by the Surveyor assay, leading to an underestimation of editing,
as previously reported (Nelson et al., 2016). The Sanger
sequencing around the target site confirmed this interpretation
and indicated that eGFP editing in neurons occurred in 9 out
of the 10 clones analyzed (Figure 1C). Finally, we tested the
CRISPR/Cas9 system on co-cultured human neurons and glialt stem cells (iPSCs), demonstrating much lower levels of eGFP fluorescence in
itive (neurons) and S100b-positive (astrocytes) cells.
the CRISPR-GFP group (n = 2, N = 1). AU: arbitrary units; bp: base pair. The
Figure 2. Human HTT Editing in HEK293T
Cells and Primary Cultures
(A) Schematic representation of the location of
the sgHTT1 target site in the human (hHTT) and
endogenous mouse (mmHTT) HTT genes. Blue:
HTT translation start site; green: sgHTT1 binding
site; red: PAM, bold-underlined nucleotide repre-
sents mismatch between sgHTT1 and the target
sequence.
(B) Efficiency of human endogenous HTT (hHTT)
editing in HEK293T cells. HEK293T cells were
transfected with plasmids encoding Cas9 and
sgHTT1 (CRISPR-HTT, n = 9, N = 2) or sgHTT1
alone (sgHTT1-only, n = 7, N = 2). Surveyor assays
showed that hHTT was efficiently edited in the
CRISPR-HTT group 7 days post-transfection.
(C and D) Direct fluorescence acquisitions re-
vealed the presence of a large number of eGFP-
positive mutant HTT aggregates in the sgHTT1-
only group (C) (n = 3, N = 1), and much lower levels
of HTT aggregation in the CRISPR-HTT group (D)
(n = 3, N = 1) 7 days post-transfection.
(E) HEK293T cells were transfected with plasmids
encoding Cas9, sgHTT1, and a fusion of the first
171 aa of the human HTT with 82 CAG and eGFP
(hHTT-82Q-eGFP, CRISPR-HTT, n = 5, N = 2). As
negative controls, cells were transfected only with
plasmids encoding sgHTT1 and hHTT-82Q-eGFP
(sgHTT1-only, n = 5, N = 2). Western blot with an
antibody directed against eGFP, demonstrating
the significantly lower levels of hHTT-82Q-eGFP
protein in the CRISPR-HTT group than in sgHTT1-
only samples, 7 days post-transfection.
(F) Western blots with an antibody recognizing the
human HTT fragment demonstrated that mutant
HTT levels were clearly lower in the CRISPR-HTT
group than in the sgHTT1-only group, 4 weeks
post-infection of primary neuronal cultures. Re-
sults are expressed as the mean ± SD. **p < 0.01,
***p < 0.001. Scale bar, 100 mm.cells derived from human iPSCs (Figures 1D and 1E). The iPSCs
were derived from a healthy subject and characterized as
previously described (Figure S5) (Boissart et al., 2013). Briefly,
we demonstrated the presence of pluripotent cells in iPSCs
as well as the absence of chromosomal abnormalities. The
neuronal cells derived from human iPSCs expressed the MAP2
and NeuN markers, and S100b was detected in immature glial
cells and GFAP in astrocytes (Figure S5). Surveyor analysis
and confocal acquisitions showed that eGFP had been edited
inmore than 30%of the cells, resulting in a strong loss of fluores-
cence in MAP2-positive neurons and S100b-positive glial cells
(Figures 1D and 1E). The LV-CRISPR/Cas9 system therefore tar-
geted genes very efficiently in both mouse and human neuronal
or glial cells.
As an application of the CRISPR/Cas9 system to neurode-
generative disorders, we targeted the gene responsible for HD
[for review, see Ross and Tabrizi (2011)]. We designed an sgRNA
(sgHTT1) targeting a region close to the translation start site of
the human HTT gene, with the aim of permanently blockingHTT expression (Figure 2A). Recently, studies demonstrated
that non-allele selective HTT silencing in the adult brain is asso-
ciated with improvements in HD pathology without deleterious
effects (Boudreau et al., 2009; Drouet et al., 2009) and a
phase I clinical trial is currently ongoing (Smith et al., 2016;
Southwell et al., 2012). Although knockout studies showed that
HTT is indispensable for embryonic development (Dragatsis
et al., 1998; Saudou and Humbert, 2016; Zeitlin et al., 1995)
and early conditional knockout leads to neuropathology (Dragat-
sis et al., 2000), or knockout on hemizygous background (Die-
trich et al., 2017) leads to neuropathology, Wang et al. (2016)
recently demonstrated that HTT ablation in adult neurons is non-
deleterious. Furthermore long-term elimination of HTT in the cor-
tex and striatum are well tolerated, supporting the design and
evaluation of global HTT editing (mutant and wild-type alleles).
Transfection experiments in HEK293T cells showed that this
sgRNA efficiently disrupted the endogenous human wild-type
HTT gene (Figures 2A and 2B). Similarly, the sgHTT1 efficiently
edited an exogenous human mutant HTT fragment fused toCell Reports 20, 2980–2991, September 19, 2017 2983
Figure 3. In Vitro HTT Editing in Primary
Cultures of Mouse Cortical Neurons and
Astrocytes
(A) Editing efficiency was evaluated for the
endogenous mouse HTT (mmHTT) in primary cul-
tures of neurons and astrocytes. Surveyor analysis
revealed an efficient editing in the CRISPR-HTT
group (neurons: n = 10, N = 2; astrocytes: n = 6,
N = 1) compared to the controls (sgHTT1-only,
neurons: n = 11, N = 2; astrocytes: n = 3, N = 1).
(B) Impact of hHTT-82Q editing in primary cultures
of cortical neurons. Cortical neuronal cultures
were infected with LV encoding Cas9, sgHTT1-
mCherry, and hHTT-82Q (CRISPR-HTT, n = 6,
N = 1). Cells infected with LV-sgHTT1-mCherry
and LV-hHTT-82Q only were used as negative
controls (sgHTT1-only, n = 6, N = 1). Surveyor
assay demonstrates an efficient hHTT-82Q editing
in the CRISPR-HTT group.
(C and D) The efficiency of hHTT-82Q editing
in cultured neurons (CRISPR-HTT: n = 5; sgHTT1-
only: n = 5) was evaluated by next-generation
sequencing (NGS). Indels were highly frequent
around the target site in the CRISPR-HTT group
(C), with more than 75% of the indels detected
resulting in frameshifts (D). Results are presented
as mean ± SD. ***p < 0.001. Scale bar, 100 mm.GFP (171 aawith 82CAG repeats; hHTT82Q-eGFP), as indicated
by the loss of GFP fluorescence (Figures 2C and 2D) and
reduced GFP-HTT protein levels on western blot (Figure 2E).
We previously showed that LV-mediated expression of an
N-terminal fragment of mutant HTT in primary cultures faithfully
reproduced gene expression changes seen in human HD,
whereas control vectors have a minimal impact on transcrip-
tional signature (Runne et al., 2008). Western blot analysis of
samples treated with CRISPR-HTT revealed a drastic reduction
of mutant HTT-82Q expression in primary cultures (Figure 2F).
Surveyor analysis in primary cultures of cortical neurons and as-
trocytes indicates that endogenous mouseHTT gene (Figure 3A)
is edited at similar efficiencies as the exogenous human HTT-
82Q (Figure 3B), confirming the potential of sgHTT1 on diploid
cells (Figure 3A). Next-generation sequencing (NGS) (MiSeq)
analysis of on-target editing revealed that 40.2% of HTT reads
contained deletions and insertions (indels) in the CRISPR-HTT
group (Figure 3C; Tables S2 and S3), with 77.1% of the indels
resulting in frameshifts (Figure 3D), in turn accounting for the
lower level of mutant hHTT-82Q protein (Figure 2F).
We then used an HD model to assess the therapeutic benefits
of disrupting themutant humanHTT gene. LV expressing the first
171 aa of the human HTT with 82 CAG repeats (hHTT-82Q) has
been used to model HD in the mouse striatum (de Almeida
et al., 2002). It caused a rapid accumulation of misfolded mutant
HTT and key dysfunctions of striatal neurons related to HD,
which were not observed in control groups expressing wild-
type hHTT-18Q or eGFP. A large proportion of NGS reads
(64%) containing indels and frameshifts were induced following
NHEJ repair in 79.9% of the sequences (Figures 4D and 4E).
Themajority of reads containing indels displayed +1-bp insertion
(>50%) and the remaining reads had mainly deletions, up to
17 bp (most often 1 and 3 bp, Tables S2 and S3). Finally,2984 Cell Reports 20, 2980–2991, September 19, 2017we showed that hHTT-82Q editing decreased aggregation of
the mutant HTT protein (36 aggregates/slice in CRISPR-HTT
group versus 171 aggregates/slice in sgHTT group) (Figures
4A and 4C) and preserved neuronal functions based on
DARPP-32 expression; a marker of GABAergic neurons func-
tionality that is decreased in HD (Figure 4B). These data demon-
strate that the CRISPR system strongly disrupted the expression
of a gene responsible for a disease in the CNS and prevented the
appearance of typical HD pathological markers.
Precision and safety are prerequisites for the use of genome-
editing tools in the study of brain disorders, and particularly for
potential therapeutic applications. Long-term immune or inflam-
matory responses due to permanent expression of the bacterial
Cas9 and off-target cleavage are key parameters of genome
editing that must be checked and are mostly context and gene
dependent (Dow et al., 2015). Blocking Cas9 expression after
HTT editing might significantly improve the final outcome of the
approach. We therefore designed a self-inactivating system
called KamiCas9. For this, an additional sgRNA, expressed
under the control of the weak 7SK promoter, targeted the ATG
of Cas9 (sgCas9) in order to block its translation (Figure 5A).
The co-transfection of HEK293T cells with plasmids encoding
eGFP, Cas9, and sgGFP1/sgCas9 led to efficient disruption of
the Cas9 sequence (Figure S6B) and a decrease in Cas9 protein
levels (Figure S6C), with no effect on eGFP editing efficiency
(Figure S6B). We then evaluated the impact of Cas9 self-inacti-
vation on HTT editing in the mouse striatum. Surveyor analysis
demonstrated a very efficient disruption ofCas9 gene (Figure 5B)
and no difference between the constitutive CRISPR-HTT and
KamiCas9-HTT on endogenous wild-type (WT) mouse HTT
(mmHTT) (Figure 5B) and exogenous mutant hHTT editing effi-
ciencies (Figure 5B). A second experiment was performed with
a Cas9 nuclease containing a V5 tag in order to perform a
Figure 4. HTT Editing In Vivo
(A) Impact of mutant human HTT editing (hHTT-82Q) in vivo. LV encoding Cas9, sgHTT1-mCherry, and hHTT-82Q (CRISPR-HTT, n = 10) were co-injected in the
striatum of WT mice. LV encoding Cas9, tdTomato-sgGFP1, and hHTT-82Q were used for the negative control group (CRISPR-GFP, n = 4). EM48 antibody
staining revealed the accumulation of misfolded mutant hHTT-82Q in the control group (n = 8) and a drastic reduction in the CRISPR-HTT group (n = 10).
(B) DARPP-32 immunostaining showing the typical downregulation in the controls (n = 10) and a reduction of DARPP-32-negative area in the CRISPR-HTT group
(n = 10).
(C) Quantification of HTT aggregates, showing lower levels of mutant HTT accumulation in the CRISPR-HTT group (n = 10) than in the negative controls (n = 8).
(D and E) The efficiency of hHTT-82Q editing (CRISPR-HTT: n = 7; sgHTT1-only: n = 3) was evaluated by NGS. Indels were highly frequent around the target site in
the CRISPR-HTT group (D), with more than 75% of the indels detected resulting in frameshifts (E). Results are presented as mean ± SD. ***p < 0.001. Scale bar,
100 mm.western blot analysis at 2months (Figure 5C). A drastic reduction
(>90%) of Cas9 protein was observed in KamiCas9-HTT-treated
animals (Figure 5D). Finally, we tested the KamiCas9 system in
10- to 18-month-old knockin mice (Ki140CAG) (Menalled et al.,
2003). Two months post-injection, indel frequencies were
analyzed with the tracking of indels by decomposition (TIDE)
method, which was developed for easy quantitative assessment
of genome editing with sequence trace decomposition (Brink-
man et al., 2014). We first validated that indel frequencies were
similar with TIDE and MiSeq analysis (Figure 4; Figure S7). In
the striatum of Ki140CAG mice, Cas9 editing reached 60.8%
(Figure 5E). However, the percentage of indels was much lower
for the mmHTT (2%–10%). This was associated with a slight
reduction of mutant mmHTT aggregates (Figure 5F), but with
no effect on rotarod motor behavior. The discrepancy between
Cas9 and mmHTT editing was also observed in WT mice (Fig-
ure 5B) and is probably explained by the presence of a mismatch
between the sgHTT1 and the mouse HTT sequence (Figure 3A),
which are affecting in vivo mmHTT editing.
We therefore privileged the use of neurons derived from pa-
tient-specific iPSCs (HD-iPSCs with 60 CAG repeats) for the final
validation and characterization of the KamiCas9-HTT system
(Figure 6). To better reveal potential differences between the
CRISPRandKamiCas9,weused suboptimal transduction condi-
tions. One to 4 weeks later, DNA, RNA, and proteins were ex-tracted from these cultures to measure the kinetics of sgRNA
synthesis (Figure 6A), Cas9 and WT/mutant HTT indel fre-
quencies (Figure 6B), and Cas9-V5 protein levels (Figure 6C).
CRIPSR-GFP and KamiCas9-GFP were used as controls. Inter-
estingly, the level of synthesis of sgHTT1 was much higher in
the CRISPR-HTT/GFP vectors than in KamiCas9-HTT/GFP,
probably due to promoter interference (Figure 6A). As expected,
theweak7SKpromoterwas leading to very lowsgCas9 synthesis
in the KamiCas9 system (10 times lower than H1-sgHTT1).
Despite the low level of sgCas9 inKamiCas9 vectors, Cas9 indels
progressively increased over time, from 15%at 1week to 58%at
4 weeks (Figure 6B). A corresponding reduction of Cas9-V5 pro-
tein was measured by western blot (Figure 6C). TIDE analysis of
the HTT gene editing confirmed that KamiCas9-HTT was as effi-
cient as the constitutive CRISPR-HTT system (Figure 6B). We
also showed that human WT and mutant endogenous HTT
were edited at similar levels (Figure 6B). Four weeks post-infec-
tion, we re-challenged HD-iPS neurons with a LV-HTT171-82Q
and measured residual editing activity 5 days later (Figure 6B).
The hHTT171-82Q editing efficiency was undetectable in the
Kamicas9-HTT group (Figure 6B), demonstrating the functional
inactivation of the nuclease with KamiCas9 vectors.
Finally, we analyzed potential off-targets. Bioinformatic
analysis identified 22 potential off-target (OT) sites in the human
genome for sgHTT1, and 5 sites for sgCas9 (Figure 7A; Tables S4Cell Reports 20, 2980–2991, September 19, 2017 2985
Figure 5. KamiCas9 Evaluation in WT and
Ki140CAG Mice
(A) Schematic representation of the sgHTT1 and
sgCas9 location in the humanHTT and Cas9 genes
and corresponding sequences. ATG: translational
start sites.
(B) Cas9 was efficiently edited in the mouse
brain (KamiCas9-HTT: n = 6; CRISPR-HTT,
n = 3; CRISPR-GFP, n = 3) with no effect on the
editing efficiency for the endogenous mouse HTT
(mmHTT) or hHTT-82Q.
(C) Cas9-V5 protein level in the striatum of C57Bl/5
mice was significantly reduced 2 months post-
injection of KamiCas9-HTT compared to CRISPR-
HTT-treated mice (KamiCas9-HTT: n = 8; CRISPR-
HTT, n = 4). As positive control, we used a protein
extract from HEK293T cells transfected with the
plasmid encoding Cas9-V5 nuclease.
(D) Quantitative analysis of the western blot.
(E) Cas9 editing measured by TIDE methods
2 months post-injection in the striatum of 10-
to 18-month-old heterozygous and homozygous
Ki140CAG mice [heterozygous KamiCas-HTT
(n = 10), KamiCas9-GFP (n = 6); homozygous
KamiCas9-HTT (n = 9), KamiCas9-GFP (n = 6)].
(F) Striatal sections from KamiCas9-GFP and
KamiCas9-HTT animals. The impact on HTT ag-
gregates was assessed with the EM48 anti-HTT
antibody. Cherry-positive staining showing striatal
neurons transduced with LV-KamiCas9-GFP and
LV-KamiCas9-HTT. Scale bar, 50 mm.
See also Figure S5.and S5). All of these sites contain at least two mismatches with
the sgRNA (Figure 7B), and a few are located within the exons
or introns of known genes (Figure 7C). Deep sequencing (MiSeq:
Mapq > 25; mean reads per off-target, 27,500) of neurons
derived from WT-iPSCs revealed undetectable off-target gene
editing for 20/21 sgHTT (no PCR product for OT5; Figure 7D)
and 5/5 sgCas9 sites (Figure 7E) as indicated by the equivalent
levels of indels in controls and edited samples. The background
levels differ betweenOT sites probably due to differences in PCR
amplification and sequencing fidelity. Importantly, if double-
strand breaks (DSBs) occur in 2.2% of the OT1 reads in
CRISP-HTT samples, the inactivation of cas9 (KamiCas9) signif-
icantly reduced this frequency (79%; Figure 7D).
In conclusion, these collective results demonstrated the high
on-target potency of KamiCas9 system in neuronal and glial cells
of the mouse brain and in cultures derived from human HD-
iPSCs. In addition, the molecular analyses demonstrated the
improved safety profile of KamiCas9, which is essential in the2986 Cell Reports 20, 2980–2991, September 19, 2017context of CNS applications and in
particular slowly progressive neurode-
generative diseases such as Huntington’s
disease.
DISCUSSION
We developed a highly efficient editing
system for CNS applications. The potencyof LV-KamiCas9 was demonstrated in mouse primary neuronal/
glial cultures, in the striatum ofmice, and in patient-specific iPSC
neuronal derivatives. We showed that the kinetics of Cas9
expression shortly followed by self-inactivation provided high
on-target editing while progressively inactivating the nuclease,
therefore preventing further on- and off-target activities.
Several inducible systems based on chemical, optical, and
transcriptional control of Cas9 RNA and protein levels have
been described (Davis et al., 2015; Dow et al., 2015; Polstein
and Gersbach, 2015; Zetsche et al., 2015). However, these stra-
tegies used complex systems or non-mammalian proteins,
which might also induce a long-term inflammatory response (Fa-
vre et al., 2002). Our method has the advantage of requiring only
the expression of an additional sgRNA and is therefore unlikely to
have any long-term effects. This lentiviral-mediated in vivo deliv-
ery also provides attractive options for spCas9 in vivo genome
editing due to its large transgene capacity. Finally, LV-KamiCas9
offers spatial and temporal control of gene editing in the CNS
Figure 6. Kinetic of KamiCas9 Editing System in HD-iPSC-Derived Neurons
(A) Neurons derived fromHD-iPSCs (60 CAG repeats) were infectedwith the KamiCas9-HTT andCRISPR-HTT systems. Two to 4weeks later, the synthesis of the
sgHTT1 and sgCas9 under the control of the H1 and 7SK promoters was measured by RT-qPCR. The level of sgHTT1 was higher in the CRISPR-HTT than in the
KamiCas9-HTT. Similarly sgCas9 levels were ten times lower than the shHTT1 in the KamiCas9 system.
(B) Sequencing of PCR products corresponding to human WT and mutant HTT revealed similar editing efficiencies. A progressive increase in Cas9 editing was
observed over time, reaching 58%at 4 weeks. At 4 weeks, we challenged the systemwith a LV-Htt171-82Q, and 5 days later we specifically measured the editing
of the mutant HTT171-82Q. This demonstrated that Cas9 self-inactivation was sufficient to prevent detectable editing.
(C) Western blot analysis showing the decrease of Cas-V5 protein at 4 weeks in the KamiCas9 samples.
(D) Quantitative analysis of Cas9 western blot at 1, 2, and 4 weeks post-infection.with opportunities tomodulate tropism and cell-type specificities
(Colin et al., 2009) as well as to integrate brain circuitry informa-
tion to reach large brain areas with local intraparenchymal ad-
ministrations (Hirano et al., 2013).
This KamiCas9 self-inactivating editing system was used to
inactivate a prototypical disease gene of the CNS, the HTT
gene (Kolli et al., 2017; Monteys et al., 2017; Shin et al., 2016;
Yang et al., 2017). These studies demonstrated an efficient
disruption of an exogenous/endogenous WT/mutant HTT
gene associated with a decreased HTT aggregation, as well as
reduced neuronal dysfunction both in vitro and in vivo. In the pre-sent study, we applied and characterized HTT gene editing in
HD-iPSC neuronal derivatives, which closely reproduce molecu-
lar and cellular features of HD (An et al., 2014; Ross and Akimov,
2014). Experiments in this model are particularly valuable not
only to assess efficacy and safety concerns but also to demon-
strate the rescue of mutant HTT phenotype following editing.
Additional studies are, however, warranted to evaluate the
consequence of non-allele selective HTT disruption with the
CRISPR/Cas9 system. Studies at the cellular level should pro-
vide data on mono- and bi-allelic editing frequencies and conse-
quences on cellular WT/mutant HTT expression levels. TheseCell Reports 20, 2980–2991, September 19, 2017 2987
Figure 7. Off-Target Analysis
(A and B) Bioinformatic analysis revealed potential off-target sites for sgHTT1 and sgCas9 (A), with at least twomismatches between the off-target sequence and
the sgRNA in each case (B).
(C) A few of these off-target sites were located in known protein-coding genes (exons or introns).
(D) sgHTT off-target analysis by NGS sequencing in neurons derived from WT-iPSCs. Differentiated neurons were infected with KamiCas9-HTT (n = 3), sgHTT/
sgCas9 (n = 2), CRISPR-HTT (n = 3), and sgHTT (n = 1). Three weeks post-infection, the DNA was extracted and the PCR products of the potential off-target sites
were analyzed by sequencing to determine the percentage of genome editing.
(E) The analysis of sgCas9 off-target sites revealed undetectable cleavage. OT, off-target.HD-iPSCs will provide an opportunity to decipher the contribu-
tion of cell-type-specific HTT functions and cellular pathways
implicated in HD in complex heterogeneous cultures. The partial
knockdown of mutant HTT expression by RNA silencing has
been shown to be sufficient to slow the progression of neuronal
dysfunction and death in various animal models of HD, and a
clinical trial based on this approach is currently underway (Smith
et al., 2016) (Roche Isis Pharmaceuticals; https://en.hdbuzz.net/
182). Genome editing has the advantage of being able to block
HTT expression in a complete and permanent manner. In addi-
tion, ATG-independent HTT translation (RAN translation) has
been observed in HD patients and can induce the accumulation
of other expanded species (Ban˜ez-Coronel et al, 2015). Frame-
shifts before the CAG expansion can lead to an early STOP
codon avoiding the synthesis of the CAG expanded track but
can also modify the reading frame to synthetize other expanded
sequences. In our study, analysis of sequencing reads demon-
strated that the majority of editedHTT alleles have either an early
STOP codon before the CAG or can induce the synthesis of an
expanded alanine-containing HTT, which has not been associ-
ated with any sign of toxicity with classical CAG length observed
in HD. The therapeutic benefits observed in our models support
the absence of toxic RAN translation following HTT ATG editing.
LV-KamiCas9-HTT is efficiently targeting the HTT loci within
the genome. However, cleavages at sites with sequences ho-
mologies with sgHTT1 and sgCas9 might occur, and the fre-2988 Cell Reports 20, 2980–2991, September 19, 2017quency of OT activities is sgRNA sequence dependent. To test
whether Kamicas9-HTT exhibits reduced off-target effects in hu-
man cells, we performed high-throughput sequencing of all OT
sites with two to four predicted mismatches in the reference hu-
man genome. The sequencing data showed that sgCas9 did not
yield any detectable off-target cleavages, supporting the use of
this sgCas9 for all KamiCas9 applications. Twenty of the 21 OT
sites were statistically indistinguishable from the background
level observed in control conditions, therefore demonstrating a
complete absence of off-target events for most sites. In OT1, a
low editing activity was detected in CRISPR-HTT samples, but
a transient expression of the Cas9 nuclease, with the Kami-
Cas9-HTT, nearly completely abrogated this off-target activity.
The use of high-fidelity Cas9 might further improve the biosafety
of the system (Kleinstiver et al., 2016; Slaymaker et al., 2016).
These data highlight the considerable potential of this strategy
for treating genetic disorders of the brain. The high editing effi-
ciency achieved in this study raises the possibility of using similar
experimental strategies for other monogenic brain diseases. In
addition, the ability of the CRISPR/Cas9 system to target multi-
ple genes simultaneously makes it a powerful tool for modeling
complex sporadic diseases developing at the interface between
genetic risk factors and a specific environment. We are confident
that this study will pave the way for further improvements
of CRISPR/Cas9 technology and its use in the adult brain to
decipher the key mechanisms underlying neurodegenerative
diseases and for the development of therapeutic approaches
based on gene editing.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
Animal Experiments
Male and female 10-week-old (adult) C57BL/6 (Janvier, Le Genest-Saint-Isle,
France) andBAC-GLT1-eGFP transgenicmice expressing eGFP specifically in
astrocytes (kindly provided by Prof. J. Rothstein, Baltimore, MD) (Regan et al.,
2007) were used for in vivo experiments. Pregnant FvB mice were used for
primary culture experiments (Janvier, Le Genest-Saint-Isle, France). Mice
were housed in a specific pathogen-free (SPF) facility with IVC cages
GM500 (Tecniplast) or rat R.BTM.U 3 /R.ICV.6 cages (Innovive) and Innorack
rats, simple face (catalog #RS.5.8.40) containing corn cob bedding with five
mice per cagemaximum. The animals weremaintained in a controlled-temper-
ature room (22 ± 1C) and under a 14-hr light/10-hr dark cycle. Breeding pro-
gram is dependent of strains or productivity requests but are regularly trio or
couple breeders. Enrichments are two pieces of wipes, one cardboard tunnel,
one cardboard or polysulfone house with two entrances/exits. Food [global
rodent diet XP-18, vitamin-fortified, irradiated at 25 kGy (Kliba Nafag AG, Kai-
seraugst, Switzerland; catalog #3242)] and water were provided ad libitum. All
experimental procedures were performed in strict accordance with Swiss
regulations concerning the care and use of laboratory animals (veterinary
authorizations: 2782, 2888, and 3073). During the surgery, body temperature
was controlled with a warming blanket (CMA 450 Temperature Controller;
Phymep, Paris, France), and the eyes were protected with 0.2% Viscotears
liquid gel (Novartis, Basel, Switzerland). Post-surgery analgesic treatment
was administered for 72 hr with paracetamol (Dafalgan Upsa; 1,000 mg/
750 mL) in the drinking water.
Ki140CAG Mice
In the present study, we used knockin mice expressing chimeric mouse/
human exon 1 containing 140 CAG repeats inserted in the murine HTT gene
(Ki140CAG). The Ki140CAG mice colony was maintained by breeding hetero-
zygotes Ki140CAG males and females (Menalled et al., 2003). Mice were N3
(B6) on a 129 Sv 3 C57BL/6J background. The characteristics of the animals
in each group are indicated in Table S1. Littermateswere used as controls. The
environment was enriched with a piece of absorbent paper. Breeder animals
also received red mouse houses. The temperature of the housed room was
controlled and maintained on a 12-hr light/dark cycle. Food and water were
available ad libitum. All animal studies were conducted according to the
French regulation (EU Directive 2010/63/EU—French Act Rural Code R 214-
87 to 131). The animal facility was approved by veterinarian inspectors (autho-
rization no. A 92-032-02) and complies with Standards for Humane Care and
Use of Laboratory Animals of the Office of Laboratory Animal Welfare
(OLAW) (no. A5826-01). All procedures received approval from the ethical
committee [authorization no. 2015060417243726vl (APAFIS#770)]. Genotype
was determined from PCR of tail snips taken at 21 days of age.
In these studies, only animals with technical failures (for example, problems
with the injection or surgery) were excluded. Animal sample size was deter-
mined based on previous studies using related experimental procedures
to allow robust statistical analyzes and reproducibility (Drouet et al., 2009,
2014). No randomization was used to allocate animals to experimental groups.
No specific order was used to treat the animals. Each in vivo experiment was
replicated ones.
Human iPSCs
Reprogramming, Culture of iPSCs
All experiments on human samples were performed in accordance with the
requirements of the Swiss ethics committee (approved protocol 107/13_3).
Human iPSCs were derived from peripheral blood mononuclear cells (PBMCs)
from a healthy subject, based on previous publications (Boissart et al., 2013;
Lee et al., 2015). iPSCs were routinely cultured and their quality was checked
(morphology, alkaline phosphatase staining, embryonic body differentiation,staining, and karyotyping), as previously described (Boissart et al., 2013;
Lee et al., 2015). The human HD-iPSC line (60 CAG HD line) from Coriell
Institute for Medical Research is cultured on L7 (Lonza) matrix in STEMPRO
medium (Invitrogen) supplemented with 10 ng/mL recombinant human
FGF2. Cells are fed daily andmanually passaged every 5–7 days. Human stria-
tal neuronal cultures with HDmutation were produced as previously described
(Arber et al., 2015; Nicoleau et al., 2013).
Differentiation, Culture of Human Neurons and Glial Cells
iPSCs from passage 20 were used for neural stem cell (NSC) differentiation, as
previously described (Boissart et al., 2013). The NSC medium was changed
every 2 days and cells were passaged once per week, as previously described
(Boissart et al., 2013). The NSCs were amplified, frozen, and stored in liquid
nitrogen until use. NSCs between passages 9 and 12 were used for differentia-
tion into neurons andglial cells. Briefly, theNSCmediumwas removed and cells
were incubated in 500 mL of trypsin (Gibco, Life Technologies, Zug, Switzerland)
at 37C for 3–5min, to detach them from the plate. Trypsin activity was inhibited
by thedirectadditionof10%FBSto theplate, andthedetachedcellswere trans-
ferred to a Falcon tube containing 4.5mL of N2B27medium (N2B27: 1:1 Neuro-
basal:DMEM-F12-Glutamax, 2% B27, 1% N2, 0.1% gentamicin; Gibco, Life
Technologies, Zug, Switzerland). Cells were centrifuged at 300 3 g for 5 min
at room temperature. The supernatant was removed, and the cells were resus-
pended in 1 mL of N2B27. NSCs were counted in a hemocytometer. For differ-
entiation into a coculture of neuronal/glial cells, we plated NSCs at a density of
50,000 NSCs/cm2 in 500 mL of medium in the wells of a 24-well plate, each well
containing a glass coverslip coated with 1/6 poly-ornithine (Sigma-Aldrich,
Buchs, Switzerland) for 24 hr and then with 2 mg/mL laminin (Sigma-Aldrich,
Buchs, Switzerland) for 24 hr. The appropriate number of NSCs were thus
transferred to a neuronal culture medium consisting of Neurobasal (Gibco, Life
Technologies, Zug, Switzerland), 2% B27 (Gibco, Life Technologies, Zug,
Switzerland), 1% Glutamax (Gibco, Life Technologies, Zug, Switzerland),
0.1% gentamicin (Gibco, Life Technologies, Zug, Switzerland), 20 ng/mL
BDNF (Miltenyi Biotech, Bergisch-Gladbach, Germany), 25 ng/mL activin A
(R&D Systems Europe, Bio-techne AG, Zug, Switzerland), and 2 mg/mL laminin
(Sigma-Aldrich, Buchs, Switzerland). The medium was completely replaced
every 3 days, and cultures were maintained for up to 6 weeks.
Culture of Human HD-NSCs
Human HD-NSCs were maintained as immature and cultured as previously
described. The NSC medium, composed of N2B27 medium with 20 ng/mL
BDNF (Miltenyi Biotech, Bergisch-Gladbach, Germany), 10 ng/mL epidermal
growth factor (EGF) (REF), and 10 ng/mL basic fibroblast growth factor
(bFGF) (REF), was changed every 2 days. Cells were passaged once per
week, at a density of 100,000 NSCs/cm2 in 500 mL of medium in the wells of
a six-well plate, coated with 1/6 poly-ornithine (Sigma-Aldrich, Buchs,
Switzerland) for 24 hr and then with 2 mg/mL laminin (Sigma-Aldrich, Buchs,
Switzerland) for 24 hr.
Statistical Methods
For the statistical analyses, normality of the distribution and equality of the
variances were assessed to determine the type of statistical tests. For two-
groups comparison, Student’s t test was performed with Excel software. For
comparisons larger than two groups, ANOVA and post hoc analyses were per-
formedwith the Statistica software. Predictive bioinformatic analyses to detect
potential off-target sites in the human genome were performed with the
CRISPRseek package with R software. For all experiments, groups of samples
were used for statistical analyzes. Statistical tests were defined as significant
if the probability of null hypothesis acceptance was below 5%. No specific
method was used for sample randomization, sample size estimation, or inclu-
sion/exclusion of data. Results are presented as the mean ± SD. *p < 0.05,
**p < 0.01, and ***p < 0.001.
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